ADMA Biologics (ADMA) Expected to Announce Quarterly Earnings on Wednesday

ADMA Biologics (NASDAQ:ADMA - Get Free Report) will likely be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect ADMA Biologics to post earnings of $0.15 per share and revenue of $112.77 million for the quarter.

ADMA Biologics Stock Down 1.5 %

Shares of ADMA stock traded down $0.24 during trading hours on Friday, hitting $15.84. 2,016,608 shares of the company were exchanged, compared to its average volume of 2,288,210. The stock has a market capitalization of $3.74 billion, a price-to-earnings ratio of 56.57 and a beta of 0.75. ADMA Biologics has a one year low of $5.08 and a one year high of $23.64. The business's 50-day simple moving average is $17.03 and its two-hundred day simple moving average is $17.88. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

Analyst Upgrades and Downgrades

A number of research analysts have commented on ADMA shares. Raymond James increased their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th. HC Wainwright raised their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.